External prescription extract for skin as well as preparation method and application of external prescription extract

By optimizing the combination of "Hyperus cream" formula and glycerol glucoside, an external skin prescription extract was prepared, which solved the problem that existing skin care products were difficult to cope with endogenous and exogenous factors at the same time, and achieved improvement of skin antioxidant and the effect of inflammatory reactions, and improve the stability of Chinese medicine extracts, suitable for improving skin condition.

CN118986845AActive Publication Date: 2024-11-22SHANDONG FREDA BIOTECH CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411176885.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-11-22
Estimated Expiration
2044-08-26

AI Technical Summary

Technical Problem

Existing skin care products are difficult to solve the damage caused to the skin by endogenous and exogenous factors, and the stability of traditional Chinese medicine extracts in cosmetics is prominent, and market application is limited.

Method used

By optimizing the "Furong Paste" formula recorded in "Integrated Traditional Chinese and Western Medicine for Treatment of Acute Abdominal Surgery", combined with glycerol glucoside, an external skin prescription extract was prepared, and the microboiling heat reflux extraction and sterilization were used to improve its stability. and efficacy, forming a composition that can resist oxidative free radicals, reduce skin inflammatory response, promote barrier-related proteins and beta-endorphins expression.

Benefits of technology

It significantly improves the anti-inflammatory, antioxidant capacity and stability of skin topical prescription extracts, can synergistically reduce UVB-induced skin barrier damage and inflammatory response, improve skin status, and is suitable for coping with endogenous and exogenous The effect of factors on the skin.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986845A_ABST
    Figure CN118986845A_ABST
Patent Text Reader

Abstract

The invention relates to an external prescription extract for skin as well as a preparation method and application thereof, and belongs to the technical field of plant extraction and cosmetic application. The invention provides a preparation method of an external skin prescription extract, the external skin prescription is obtained by optimizing cottonrose hibiscus paste recorded in'treatment of acute abdominal syndrome by combining traditional Chinese medicine and western medicine ', the medicinal materials comprise cottonrose hibiscus leaves, rheum officinale, herba lycopi leaves, golden cypress, coptis chinensis, scutellaria baicalensis and borneol, and the obtained external skin prescription extract is higher in flavonoid active substance content and better in curative effect. The anti-inflammatory and anti-oxidation capacities are higher, and the stability is higher. Besides, the composition composed of the skin external prescription extract and glycosylglycerol has a synergistic effect on reducing skin inflammatory response and promoting expression of barrier-related protein and beta-ennorphin, so that the influence of endogenous and exogenous factors on the skin is coped with at the same time, and the effect of improving the skin state is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a skin external prescription extract and a preparation method and application thereof, belonging to the technical field of plant extraction and cosmetic application. Background Art

[0002] As the outermost barrier of the human body, the skin is very important for protecting the body from damage by external factors and maintaining the homeostasis of the human body's internal environment. Exogenous factors such as environmental pollution, ultraviolet rays, cooking, or endogenous factors such as anxiety and work pressure can cause damage to the skin. Currently, most skin care products on the market are designed to protect or repair skin damage caused by exogenous factors. There are very few raw materials or skin care products that target skin damage caused by endogenous factors, and there are even fewer raw materials or skin care products that can solve the skin problems caused by both.

[0003] The skin is an organ that reflects emotions. Long-term anxiety, stress, lack of sleep, and other negative emotions can affect the skin condition, which manifests as barrier dysfunction, reduced wound healing ability, and abnormal skin immune function. The main mechanism is that psychological stress stimulates the hypothalamus-pituitary-adrenal axis (HPA axis) to secrete a variety of hormones. These hormones can reach the skin tissue through blood circulation or other transmission methods, and regulate the skin condition by binding to the corresponding receptors expressed by skin cells. β-endorphin is one of the hormones, which is processed by pro-opiomelanocortin (POMC). It is expressed in various tissues such as the pituitary gland, brain, adrenal glands, and skin, and participates in the repair process of various skin problems. For example, β-endorphin can regulate the function of Langerhans cells by regulating the expression of interleukin 1β (IL-1β) and interleukin 10 (IL-10), and participates in skin immune regulation; β-endorphin can promote the growth and migration of keratinocytes and promote skin repair. When the human body is in a negative mood for a long time, it will affect the expression of β-endorphin, thereby affecting the normal physiological function of the skin. Therefore, promoting the expression of β-endorphin is one of the important ways to solve endogenous skin problems.

[0004] Patent application CN117357421A provides a composition containing ergothioneine and dipeptide-1 or its derivatives, which can synergistically promote the expression of proopiomelanocortin or β-endorphin. However, ergothioneine has poor stability under light or high temperature conditions and is expensive, which is not conducive to its widespread application.

[0005] Patent application CN116785209A provides an agarwood hydrosol extract that can repair skin problems caused by exogenous stimulation and endogenous stress, can target and regulate the expression of TRPV1 receptors, improve skin sensory nerve dysfunction, promote β-endorphin secretion, and solve skin problems caused by stress. However, agarwood hydrosol itself contains aromatic ingredients, and consumers have different acceptance of the smell, so the market acceptance is low, which is not conducive to product promotion.

[0006] Traditional Chinese medicine is a treasure of Chinese civilization and has a high development value. The "Hibiscus Paste" recorded in "Treatment of Acute Abdomen with Integrated Traditional Chinese and Western Medicine" is composed of 8 liang of Hibiscus Leaves, 8 liang of Rhubarb, 8 liang of Ze Lan Leaves, 8 liang of Phellodendron, 6 liang of Scutellaria, 6 liang of Coptis, and 2 qian of Borneol. It has the effect of clearing away heat, detoxifying and reducing swelling, and can relieve the skin redness and discomfort caused by mosquito bites, skin eczema, furuncle, etc. Patent application CN106038780A in the prior art provides a Chinese medicine cream for anti-erysipelas, swelling and mumps, including Hibiscus Leaves, Raw Rhubarb, Phellodendron, Scutellaria, Ze Lan Leaves, Coptis, Da Pi Xiao, and Borneol. It has the effects of clearing heat and cooling blood, reducing swelling and relieving pain, and can resist erysipelas, cellulitis, etc., but the prescription form is medicinal and difficult to be applied in the field of cosmetics. Patent application CN107007622A provides a myogenic composition for promoting skin soft tissue regeneration, which contains hibiscus leaves, rhubarb, zedoaria leaves, phellodendron, scutellaria, coptis root, borneol, etc., which can improve the problem of wound redness, swelling and inflammation, but it can only solve skin problems caused by exogenous factors. In addition, the stability of Chinese herbal medicine extracts has always been a problem that plagues their application in cosmetics. How to improve the stability of raw materials through technology is also a problem that needs to be solved urgently in the industry. Summary of the invention

[0007] In view of the deficiencies of the prior art, the present invention provides a skin topical prescription extract and a preparation method and application thereof. The skin topical prescription extract prepared by the present invention can effectively resist oxidative free radicals, reduce skin inflammatory reactions, and promote the expression of barrier-related proteins. The efficacy and stability of the skin topical prescription extract obtained by process optimization have been significantly improved, which is more conducive to its application. In addition, the present invention unexpectedly discovered that the composition of the skin topical prescription extract and glycerol glucoside has a synergistic effect in reducing skin inflammatory reactions and promoting the expression of barrier-related proteins and β-endorphin, thereby simultaneously coping with the effects of endogenous and exogenous factors on the skin and improving the skin condition.

[0008] The technical solution of the present invention is as follows:

[0009] In a first aspect, the present invention provides a method for preparing an extract of a skin external application prescription, comprising the following steps:

[0010] S1. The medicinal materials of the external skin prescription are crushed separately, passed through a 10-50 mesh sieve, and the sieve portion is taken. The medicinal materials are mixed in a certain proportion and then mixed with an extraction solvent in a certain material-liquid ratio, and extracted by slightly boiling reflux to obtain a crude extract;

[0011] S2. The crude extract obtained in step S1 is filtered through a filter cloth to remove the drug residue, brought to room temperature, and filtered through a filter plate. After the filtrate is sterilized, it is allowed to stand at room temperature or low temperature for 24 to 48 hours to obtain a secondary filtrate;

[0012] S3. The secondary filtrate obtained in step S2 is filtered through a filter plate again, a preservative and a stabilizer are added, and the mixture is stirred at 45°C to 55°C until it is completely dissolved, thereby obtaining an extract for external use on the skin.

[0013] Preferably, the skin topical prescription in step S1 is optimized from the "Hibiscus Paste" recorded in "Treatment of Acute Abdomen with Integrated Traditional Chinese and Western Medicine", and the medicinal materials include hibiscus leaves, rhubarb, zedoaria leaves, phellodendron, coptis chinensis, scutellaria baicalensis, and borneol, wherein the mass ratio of hibiscus leaves, rhubarb, zedoaria leaves, phellodendron, coptis chinensis, scutellaria baicalensis, and borneol when mixed is 80:80:1:100:80:80:2.

[0014] Preferably, in step S1, the product is sieved through a 10-mesh sieve.

[0015] Preferably, the extraction solvent in step S1 is a 30% to 35% 1,3-butanediol aqueous solution; more preferably, it is a 30% 1,3-butanediol aqueous solution, all of which are mass percentages.

[0016] Preferably, the material-liquid ratio in step S1 is 1:(28-32); more preferably 1:30.

[0017] Preferably, the temperature of the slightly boiling hot reflux extraction in step S1 is 90-100° C., and the time is 2-4 hours; more preferably, the slightly boiling hot reflux extraction is performed at 100° C. for 3.5 hours.

[0018] Preferably, the filter cloth in step S2 is a double-layer filter cloth with a mesh size of 200 to 400; more preferably, it is a double-layer filter cloth with a mesh size of 300.

[0019] Preferably, the filter plate in step S2 is a 0.22 μm or 0.45 μm filter plate.

[0020] Preferably, the sterilization in step S2 is performed at 121° C. for 20 min.

[0021] Preferably, in step S2, the mixture is allowed to stand at room temperature for 36 hours.

[0022] Preferably, the low temperature in step S2 is 2-6°C.

[0023] Preferably, the filter plate in step S3 is a 0.22 μm or 0.45 μm filter plate.

[0024] Preferably, the preservative in step S3 is a combination of one or more of 1,2-hexanediol, p-hydroxyacetophenone, and 1,2-pentanediol; further preferably, the preservative is a combination of 1,2-hexanediol, p-hydroxyacetophenone, and 1,2-pentanediol.

[0025] More preferably, in the extract of the external skin preparation, the final concentration of p-hydroxyacetophenone is 0.3-0.6 wt %, the final concentration of 1,2-hexanediol is 0.5-2 wt %, and the final concentration of 1,2-pentanediol is 0.5-2 wt %.

[0026] Preferably, the stabilizer in step S3 is polysorbate 20.

[0027] More preferably, in the extract for external skin application, the final concentration of polysorbate-20 is 1 to 5 wt %.

[0028] In a second aspect, the present invention provides a skin external application prescription extract prepared according to the above preparation method.

[0029] In a third aspect, the present invention provides a composition for improving skin condition, comprising the above-mentioned skin external prescription extract and glycerol glucoside.

[0030] In the present invention, the glycerol glucoside is a commercially available product or is prepared according to the prior art.

[0031] Preferably, in the system containing the composition of the extract of the skin external prescription and glycerol glucoside, the final concentration of the extract of the skin external prescription is 0.5-6.0 wt %, and the final concentration of the glycerol glucoside is 0.1-2.0 wt %.

[0032] More preferably, in the system containing the composition of the skin external prescription extract and glycerol glucoside, the final concentration of the skin external prescription extract is 1.0-4.0 wt %, and the final concentration of the glycerol glucoside is 1.0-2.0 wt %.

[0033] In the present invention, the system of the composition containing the extract of the external skin prescription and glyceryl glucoside may include purified water or other conventional cosmetic or skin care product bases in addition to the extract of the external skin prescription and glyceryl glucoside.

[0034] In the present invention, the composition of the above-mentioned skin external prescription extract and glycerol glucoside can reduce skin inflammatory response and promote the expression of barrier-related proteins and β-endorphin through synergistic effects, thereby simultaneously coping with the effects of endogenous and exogenous factors on the skin and improving the skin condition.

[0035] In a fourth aspect, the use of the composition of the skin external prescription extract and glycerol glucoside in the preparation of cosmetics or skin care products.

[0036] Preferably, the cosmetic or skin care product is in the form of liquid, gel, ointment, cream, lotion, facial mask or freeze-dried powder.

[0037] A fifth aspect is a cosmetic or skin care product comprising a composition of the above-mentioned skin external application prescription extract and glyceryl glucoside.

[0038] In the present invention, the cosmetics or skin care products can be used on the skin surface to reduce skin inflammatory reactions and promote the expression of barrier-related proteins and β-endorphin through synergistic effects, thereby simultaneously coping with the effects of endogenous and exogenous factors on the skin and improving the skin condition.

[0039] Beneficial effects:

[0040] 1. The present invention provides a method for preparing an extract for external use on the skin, and the obtained extract for external use on the skin has a higher content of flavonoid active substances, stronger anti-inflammatory and antioxidant abilities, and is more stable.

[0041] 2. The present invention also provides a composition composed of a skin external prescription extract and glycerol glucoside, which: 1) can significantly reduce UVB-induced skin barrier damage by increasing the mRNA expression of filaggrin (FLG), play a role in repairing the skin barrier and improving skin photodamage, and can synergize; 2) can significantly reduce UVB-induced skin inflammatory response by inhibiting the secretion of tumor necrosis factor α (TNF-α), play a role in soothing skin inflammation and improving skin photodamage, and can synergize; 3) can respond to endogenous skin problems by increasing the content of β-endorphin, play a role in improving skin conditions, and can synergize. Based on the above technical effects, it is possible to simultaneously respond to the effects of endogenous and exogenous factors on the skin and improve the skin conditions. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 is the standard curve of flavonoid content with rutin as the standard;

[0043] Figure 2It is a bar graph of the expression of FLG mRNA in HaCaT cells under the action of the compositions of Examples 4 to 8 and Comparative Examples 14 to 18;

[0044] Figure 3 It is a bar graph of the secretion amount of TNF-α of HaCaT cells under the action of the compositions of Examples 4 to 8 and Comparative Examples 14 to 18;

[0045] Figure 4 It is a bar graph of the β-endorphin content of HaCaT cells under the action of the compositions of Examples 4 to 8 and Comparative Examples 14 to 18;

[0046] In the figure, compared with the blank control group, the significance is indicated by #, 0.01<P<0.05 is indicated by #, 0.001<P<0.01 is indicated by ##, 0.0001<P<0.001 is indicated by ###, and P<0.0001 is indicated by ####; compared with the negative control group, the significance is indicated by *, 0.01<P<0.05 is indicated by *, 0.001<P<0.01 is indicated by **, 0.0001<P<0.001 is indicated by ***, and P<0.0001 is indicated by ****. DETAILED DESCRIPTION

[0047] In order to better understand the present invention, the following is further described in conjunction with the embodiments, but the protection scope of the present invention is not limited to the following embodiments, and the embodiments should not be regarded as limiting the protection scope of the present invention.

[0048] The external skin prescription described in the embodiments and comparative examples is optimized from the "Hibiscus Paste" recorded in "Treatment of Acute Abdomen with Integrated Traditional Chinese and Western Medicine", and the medicinal materials include: Hibiscus mutabilis leaves, rhubarb, Zedoariae leaves, Phellodendron amurense, Coptis chinensis, Scutellaria baicalensis, and borneol.

[0049] The rhubarb, hibiscus mutabilis leaf, zedoaria leaf, phellodendron, coptis root, borneol and scutellaria involved in the embodiments and comparative examples are all common commercial products. The other reagents and materials involved in the embodiments and comparative examples are all common commercial products unless otherwise specified.

[0050] The glycerol glucoside described in the present invention is a commercially available product or is prepared according to the prior art. The glycerol glucoside used in the embodiments and comparative examples was purchased from Hubei Xinyuhong Biopharmaceutical Technology Co., Ltd.

[0051] Example 1

[0052] A method for preparing a skin external prescription extract comprises the following steps:

[0053] S1. The medicinal materials of the external skin prescription are crushed separately, passed through a 10-mesh sieve, and the sieve portion is taken. Hibiscus mutabilis leaves, rhubarb, zedoaria leaves, phellodendron, coptis root, scutellaria baicalensis and borneol are mixed at a mass ratio of 80:80:1:100:80:80:2, and after mixing, 30% 1,3-butanediol aqueous solution is added to an extraction tank at a material-liquid ratio of 1:30, and extracted at 100°C with slight boiling reflux for 3.5 hours to obtain a crude extract;

[0054] S2. The crude extract obtained in step S1 was filtered through a double-layer 300-mesh filter cloth to remove the drug residue, allowed to cool to room temperature, and filtered through a 0.45 μm filter plate. The filtrate was sterilized at 121°C for 20 min and allowed to stand at room temperature for 36 h to obtain a secondary filtrate;

[0055] S3. After filtering the secondary filtrate obtained in step S2 through a 0.45 μm filter plate, add 0.5 wt% of p-hydroxyacetophenone, 2 wt% of 1,2-hexanediol, and 1 wt% of 1,2-pentanediol as preservatives, and 1 wt% of polysorbate-20 as a stabilizer at a final concentration of 1 wt%, and stir at 45° C. to 55° C. until completely dissolved to obtain an extract for external use on the skin.

[0056] Example 2

[0057] A method for preparing a skin external prescription extract comprises the following steps:

[0058] S1. The medicinal materials of the external skin prescription are crushed separately, passed through a 30-mesh sieve, and the sieve portion is taken. Hibiscus mutabilis leaves, rhubarb, zedoaria leaves, phellodendron, coptis root, scutellaria baicalensis and borneol are mixed at a mass ratio of 80:80:1:100:80:80:2, and after mixing, 30% 1,3-butanediol aqueous solution is added to an extraction tank at a material-liquid ratio of 1:30, and extracted at 100°C with slight boiling reflux for 2 hours to obtain a crude extract;

[0059] S2. The crude extract obtained in step S1 was filtered through a double-layer 200-mesh filter cloth to remove the drug residue, cooled to room temperature, and filtered through a 0.45 μm filter plate. The filtrate was sterilized at 121°C for 20 min and then allowed to stand at low temperature (4°C) for 24 h to obtain a secondary filtrate;

[0060] S3. After filtering the secondary filtrate obtained in step S2 through a 0.45 μm filter plate, add 0.6 wt% of p-hydroxyacetophenone, 0.5 wt% of 1,2-hexanediol, and 2 wt% of 1,2-pentanediol as preservatives, and 3 wt% of polysorbate-20 as a stabilizer, and stir at 45° C. to 55° C. until completely dissolved to obtain an extract for external use on the skin.

[0061] Example 3

[0062] A method for preparing a skin external prescription extract comprises the following steps:

[0063] S1. The medicinal materials of the external skin prescription are crushed separately, passed through a 50-mesh sieve, and the sieve portion is taken. Hibiscus mutabilis leaves, rhubarb, zedoaria leaves, phellodendron, coptis root, scutellaria baicalensis and borneol are mixed at a mass ratio of 80:80:1:100:80:80:2, and after mixing, 30% 1,3-butanediol aqueous solution is added to an extraction tank at a material-liquid ratio of 1:30, and extracted at 100°C with slight boiling reflux for 4 hours to obtain a crude extract;

[0064] S2. The crude extract obtained in step S1 was filtered through a double-layer 400-mesh filter cloth to remove the drug residue, allowed to cool to room temperature, and filtered through a 0.45 μm filter plate. The filtrate was sterilized at 121°C for 20 min and allowed to stand at room temperature for 48 h to obtain a secondary filtrate;

[0065] S3. After filtering the secondary filtrate obtained in step S2 through a 0.45 μm filter plate, add 0.3 wt% of p-hydroxyacetophenone, 1 wt% of 1,2-hexanediol, and 0.5 wt% of 1,2-pentanediol as preservatives, and 5 wt% of polysorbate-20 as a stabilizer, and stir at 45° C. to 55° C. until completely dissolved to obtain an extract for external use on the skin.

[0066] Comparative Example 1

[0067] A method for preparing an extract for external use on the skin, which differs from Example 1 in that the mass ratio of Hibiscus mutabilis leaves, Rhubarb, Zedoariae rhizome leaves, Phellodendron amurense, Coptis chinensis, Scutellaria baicalensis and Borneol is 40:40:40:40:30:30:1.

[0068] Comparative Example 2

[0069] A method for preparing an extract of a skin external prescription, which is different from Example 1 in that the medicinal materials of the skin external prescription do not contain Hibiscus mutabilis leaves.

[0070] Comparative Example 3

[0071] A method for preparing an extract of a skin external prescription, which is different from Example 1 in that the medicinal materials of the skin external prescription do not contain rhubarb.

[0072] Comparative Example 4

[0073] A method for preparing an extract of a prescription for external use on the skin, which is different from Example 1 in that the medicinal materials of the prescription for external use on the skin do not contain Scutellaria baicalensis.

[0074] Comparative Example 5

[0075] A method for preparing an extract for external use on the skin, which is different from that of Example 1 in that the mass ratio of Hibiscus mutabilis leaves, Rhubarb, Zedoariae rhizome leaves, Phellodendron amurense, Coptis chinensis, Scutellaria baicalensis and Borneol is 40:40:10:50:40:40:1.

[0076] Comparative Example 6

[0077] A method for preparing an extract for external use on the skin, which is different from that of Example 1 in that the mass ratio of Hibiscus mutabilis leaves, Rhubarb, Zedoariae rhizome leaves, Phellodendron amurense, Coptis chinensis, Scutellaria baicalensis and Borneol is 80:80:1:120:80:80:2.

[0078] Comparative Example 7

[0079] A method for preparing an extract for external use on the skin, which differs from Example 1 in that the mass ratio of Hibiscus mutabilis leaves, Rhubarb, Zedoariae rhizome leaves, Phellodendron amurense, Coptis chinensis, Scutellaria baicalensis and Borneol is 80:80:1:100:100:80:2.

[0080] Comparative Example 8

[0081] A method for preparing an extract of a prescription for external use on skin, which differs from that of Example 1 in that the extraction solvent in step S1 is 75% ethanol.

[0082] Comparative Example 9

[0083] A method for preparing an extract for external skin application, which differs from that of Example 1 in that the material-liquid ratio in step S1 is 1:20.

[0084] Comparative Example 10

[0085] A method for preparing an extract for external skin application, which differs from that of Example 1 in that the material-liquid ratio in step S1 is 1:40.

[0086] Comparative Example 11

[0087] A method for preparing an extract for external skin application, which differs from Example 1 in that no stabilizer is added in step S3.

[0088] Comparative Example 12

[0089] A method for preparing an extract for external skin application, which differs from Example 1 in that trehalose with a final concentration of 3% is added as a stabilizer in step S3.

[0090] Comparative Example 13

[0091] A method for preparing an extract for external skin application, which differs from Example 1 in that xanthan gum with a final concentration of 0.1% is added as a stabilizer in step S3.

[0092] Examples 4 to 8 and Comparative Examples 14 to 18

[0093] A composition comprising the extract of the skin external prescription and glycerol glucoside. Table 1 shows the composition of the composition for improving skin condition of Examples 4 to 8, which synergistically reduces skin inflammatory response and promotes the expression of barrier-related proteins and β-endorphin, thereby simultaneously coping with the effects of endogenous and exogenous factors on the skin, and plays a role in improving skin condition. For comparison, Table 1 also provides Comparative Examples 14 to 18, wherein Comparative Examples 14 to 15 differ from Examples 4 to 8 in that they contain only one substance in the composition, Comparative Examples 16 to 17 differ from Examples 4 to 8 in that one of the substances in the composition exceeds the protection scope, and Comparative Example 18 differs from Examples 4 to 8 in that the extract of the skin external prescription used is different.

[0094] Table 1. Raw material components and proportions of the compositions of Examples 4 to 8 and Comparative Examples 14 to 18, unit: wt%

[0095]

[0096]

[0097] Note: * indicates that the skin external prescription extract used in Comparative Example 18 is the skin external prescription extract prepared according to the preparation method of Comparative Example 1. The skin external prescription extracts used in the remaining examples and comparative examples are all skin external prescription extracts prepared according to the preparation method of Example 1.

[0098] Example 9 and Comparative Example 19

[0099] The composition of the skin external prescription extract and glycerol glucoside prepared according to the preparation method of Example 1 was added to a skin care cream to prepare a skin care product with the effect of improving skin condition, i.e., Example 9. At the same time, a placebo group, i.e., Comparative Example 19, was set up. The difference between Comparative Example 19 and Example 9 is that Comparative Example 19 does not contain a composition composed of the skin external prescription extract and glycerol glucoside. The specific raw material ingredients and proportions are shown in Table 2. Human efficacy experiments were carried out to test its effect of improving skin condition.

[0100] Table 2. Raw material ingredients and proportions of skin care creams of Example 9 and Comparative Example 19

[0101]

[0102]

[0103] The skin care creams of Example 9 and Comparative Example 19 were both prepared by conventional methods in the art.

[0104] Experimental example:

[0105] The performance tests of the products of the above embodiments and comparative examples are as follows:

[0106] Experimental Materials:

[0107] The human immortalized keratinocytes (HaCaT cells) used in the following tests can be purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences; other reagents and materials are common commercial products unless otherwise specified.

[0108] 1. Antioxidant Properties

[0109] The antioxidant properties of the skin external prescription extracts prepared in Examples 1 to 3 and Comparative Examples 1 to 10 were determined by a DPPH free radical scavenging experiment.

[0110] Preparation of DPPH working test solution (concentration is 0.08 mg / mL): Accurately weigh 20 mg of DPPH powder, add anhydrous ethanol to dissolve, and make up to volume in a 250 mL volumetric flask, store at 0-4°C away from light, and use it immediately after preparation.

[0111] Preparation of test solutions: dilute the skin external prescription extract samples with purified water to obtain test solutions with sample concentrations of 0.5wt%, 0.8wt%, 1.0wt%, 1.5wt%, 2.5wt%, 3.0wt%, 5.0wt%, and 6.0wt%.

[0112] The detection method, steps are as follows:

[0113] S1. Mix 1 mL of the test solution with 1 mL of 0.08 mg / mL DPPH solution (tube A);

[0114] S2. Mix 1 mL of anhydrous ethanol and 1 mL of 0.08 mg / mL DPPH solution (tube B);

[0115] S3. Mix 1 mL of anhydrous ethanol with 1 mL of the test solution (tube C);

[0116] S4. After 30 minutes of reaction in the dark, pipette 200 μL of the reaction solution into a 96-well plate in the dark, and then measure the absorbance OD of tubes A, B, and C at 517 nm. Calculate the DPPH clearance rate according to the following formula:

[0117] DPPH clearance rate (%) = (OD B +OD C -OD A ) / OD B ×100%

[0118] Among them, the DPPH free radical scavenging rate measurement results of Examples 1 to 3 and Comparative Examples 1 to 7 are shown in Table 3; the DPPH free radical scavenging rate measurement results of Examples 1 to 3 and Comparative Examples 8 to 10 are shown in Table 4.

[0119] Table 3. DPPH free radical scavenging rate determination results of Examples 1 to 3 and Comparative Examples 1 to 7

[0120]

[0121] The results in Table 3 show that under the same process, when the mass ratio of Hibiscus mutabilis leaves, rhubarb, Zedoariae leaves, Phellodendron chinense, Coptis chinensis, Scutellaria baicalensis and Borneolum in Examples 1 to 3 is 80:80:1:100:80:80:2, the DPPH free radical scavenging effect is the best. When one of the substances is missing or the ratio of the substances is changed, the DPPH free radical scavenging effect of Comparative Examples 1 to 4 is lower than that of Examples 1 to 3 under the same detection conditions. When the ratio of a certain substance is increased, the DPPH free radical scavenging effect of Comparative Examples 5 to 7 is not significantly improved compared with Examples 1 to 3 under the same detection conditions, but is reduced.

[0122] Table 4. DPPH free radical scavenging rate determination results of Examples 1 to 3 and Comparative Examples 8 to 10

[0123]

[0124]

[0125] The results in Table 4 show that under the same medicinal material ratio, the DPPH radical scavenging effect of the skin external prescription extracts prepared by the methods of Examples 1 to 3 is better, and by replacing the extraction solvent or changing the material-liquid ratio, under the same detection conditions, the DPPH radical scavenging effect of the skin external prescription extracts of Comparative Examples 8 to 10 is lower than that of Examples 1 to 3.

[0126] 2. Anti-inflammatory performance testing

[0127] COX-2 (cyclooxygenase-2) is an inflammatory factor. The extracts of the skin external prescriptions obtained in Examples 1 to 3 and Comparative Examples 1 to 10 were diluted to 0.5wt%, 0.8wt%, 1.0wt%, 1.5wt%, 2.5wt%, 3.0wt%, 5.0wt%, and 6.0wt% respectively using DMSO, and the COX-2 inhibition rate was determined according to the kit instructions to reflect its anti-inflammatory activity. The COX-2 inhibitor screening kit used was purchased from Shanghai Bio-Tech Biotechnology Co., Ltd.

[0128] The results of the COX-2 inhibition rate determination of Examples 1 to 3 and Comparative Examples 1 to 7 are shown in Table 5; the results of the COX-2 inhibition rate determination of Examples 1 to 3 and Comparative Examples 8 to 10 are shown in Table 6.

[0129] Table 5. COX-2 inhibition rate measurement results of Examples 1 to 3 and Comparative Examples 1 to 7

[0130]

[0131] The results in Table 5 show that under the same process, when the mass ratio of Hibiscus mutabilis leaves, Rhubarb, Zedoariae leaves, Phellodendron amurense, Coptis chinensis, Scutellaria baicalensis and Borneol in Examples 1 to 3 is 80:80:1:100:80:80:2, the inhibition effect on COX-2 is the best. When one of the substances is missing or the proportion of the substances is changed, under the same detection conditions, the inhibition rates of Comparative Examples 1 to 4 on COX-2 are all lower than those of Examples 1 to 3. When the proportion of a certain substance is increased, under the same detection conditions, the inhibition rates of Comparative Examples 5 to 7 on COX-2 have no obvious improvement compared with Examples 1 to 3, but have decreased.

[0132] Table 6. COX-2 inhibition rate measurement results of Examples 1 to 3 and Comparative Examples 8 to 10

[0133]

[0134] The results in Table 6 show that under the same ratio of medicinal materials, the extracts of the skin external prescriptions prepared by the methods of Examples 1 to 3 have better inhibitory effects on COX-2. When the extraction solvent is replaced or the material-liquid ratio is changed, under the same detection conditions, the inhibitory effects of Comparative Examples 8 to 10 on COX-2 are all lower than those of Examples 1 to 3.

[0135] 3. Flavonoid content detection

[0136] Take 1 mL of the skin external prescription extract samples of Examples 1 to 3 and Comparative Examples 8 to 10 in test tubes, add 4 mL of purified water, 0.3 mL of 5% NaNO 2 After mixing for 5 min, 0.3 mL of 10% Al(NO 3 ) 3 After 6 minutes of reaction, 2 mL of 1 mol / L NaOH aqueous solution and 2.4 mL of purified water were added in sequence. After 10 minutes, the absorbance was measured at 510 nm. A standard curve was drawn with the absorbance value A as the ordinate and the concentration of the rutin standard as the abscissa, and the total flavonoid content of the sample to be tested was calculated based on the standard curve.

[0137] Figure 1 is the standard curve of flavonoid content based on rutin standard, and the standard curve equation is y=0.1636x+0.1624, R 2 =0.9962, and the total flavonoids content of the skin external prescription extracts of Examples 1 to 3 and Comparative Examples 8 to 10 was calculated based on the absorbance values. The results are shown in Table 7.

[0138] Table 7. Determination results of total flavonoid content in Examples 1 to 3 and Comparative Examples 8 to 10

[0139] Group Example 1 Example 2 Example 3 Comparative Example 8 Comparative Example 9 Comparative Example 10 Total flavonoids content 2.95±0.01 2.43±0.01 2.64±0.01 0.38±0.04 0.65±0.04 0.42±0.01

[0140] The results in Table 7 show that under the preparation methods of Examples 1 to 3, the total flavonoid content is higher, and when the extraction solvent is replaced or the material-liquid ratio is changed in Comparative Examples 8 to 10, the total flavonoid content is lower than that of Examples 1 to 3.

[0141] 4. Stability comparison

[0142] The skin external prescription extracts prepared in Examples 1 to 3 and Comparative Examples 8 to 13 were placed under low temperature (-20°C), refrigeration (4°C), high temperature (50°C), alternating hot and cold (55°C / -20°C, alternating every other day) and light (4500±500LX) conditions, and the stability of different skin external prescription extracts under different storage conditions was observed within 90 days. The results are shown in Table 8. Within 90 days, the skin external prescription extracts of Examples 1 to 3 and Comparative Examples 8 to 10 were all in a stable state under different storage conditions, while Comparative Examples 11 to 13 had precipitation at different time periods, and the precipitation would gradually increase with the extension of time, affecting its application.

[0143] Table 8. Stability test results of Examples 1 to 3 and Comparative Examples 8 to 13

[0144]

[0145] V. Composition efficacy test

[0146] (1) Effects of the compositions of Examples 4 to 8 and Comparative Examples 14 to 18 on the expression of FLG mRNA in HaCaT cells

[0147] Human immortalized keratinocytes (HaCaT cells) with good growth status were collected and cell suspension was prepared with DMEM complete culture medium. The cell concentration of the suspension was adjusted to 1.3×10 5 / mL, 2mL of cell suspension was added to each well of a 6-well cell culture plate. The experiment set up a blank control group (DMEM high-glucose culture medium), a negative control group (UVB+DMEM high-glucose culture medium), and a sample group (UVB+DMEM high-glucose culture medium containing the composition of Examples 4 to 8 and Comparative Examples 14 to 18), and 3 parallels were set for each group. The inoculated 6-well cell culture plate was placed in a cell culture incubator (5% CO 2 , 37°C) for 24 h. When the cell fusion rate reached 40-60%, the culture medium was discarded and PBS buffer was added. Except for the blank control group, each group was given 43 mJ / cm 2After the irradiation, the PBS buffer was discarded, and the blank control group and the negative control group were added with DMEM high-glucose culture medium, and the remaining groups were added with DMEM high-glucose culture medium containing the compositions of Examples 4 to 8 and Comparative Examples 14 to 18, respectively, and cultured in a cell culture incubator for 24 hours, and the culture medium was discarded, and the total RNA of each group of cells was extracted, and the mRNA expression of FLG was detected by RT-qPCR.

[0148] The test concentrations of the compositions of Examples 4 to 8 and Comparative Examples 14 to 18 are shown in Table 1, and the solvent is DMEM high-glucose culture medium.

[0149] FLG is an important molecule that connects keratin fibers in the stratum corneum of human skin. With the help of FLG monomers, keratin fibers gather regularly and form a solid physical barrier in the outermost layer of the epidermis, which can prevent the loss of epidermal moisture and the invasion of harmful substances from the outside world. The test results are shown in Table 9 and Figure 2 As shown, after UVB stimulation, the mRNA expression of FLG in the negative control group was significantly lower than that in the blank control group (P<0.0001), proving that the light damage model was successfully modeled. After UVB stimulation, compared with the negative control group, after adding the compositions of Examples 4 to 8 and Comparative Examples 14 to 18 to the damaged cells, the mRNA expression of FLG was significantly increased (P<0.001), wherein the increase rates of the compositions of Examples 4 to 8 on the mRNA expression of FLG were 473.90%, 400.97%, 372.91%, 352.05%, and 362.75%, respectively, and the increase rates of the compositions of Comparative Examples 14 to 18 on the mRNA expression of FLG were 197.71%, 101.93%, 314.37%, 317.07%, and 259.75%, respectively. The results of Comparative Examples 14 and 15 show that the use of skin external prescription extract or glycerol glucoside alone has a certain effect on improving the expression of FLG mRNA, but compared with the results of Examples 4 to 8, it can be seen that the improvement effect is better when the two are used in combination, indicating that the composition of skin external prescription extract and glycerol glucoside can significantly reduce UVB-induced skin barrier damage by increasing the mRNA expression of FLG, play a role in repairing the skin barrier and improving skin photodamage, and can synergistically enhance the effect. Comparative Examples 16 and 17 can be compared with the results of Examples 4 to 8. It can be seen that after one of the skin external prescription extract and glycerol glucoside exceeds a certain concentration range, the increase in content does not increase the effect of the composition on the improvement of FLG mRNA expression. At the same time, compared with the results of Example 4, it can be seen that the skin external prescription extract and glycerol glucoside used in the embodiment of the present invention are used in combination. The effect is better.

[0150] Table 9. Effects of the compositions of Examples 4 to 8 and Comparative Examples 14 to 18 on the expression of FLG mRNA in HaCaT cells

[0151]

[0152]

[0153] (2) Effects of the compositions of Examples 4 to 8 and Comparative Examples 14 to 18 on TNF-α secretion in HaCaT cells

[0154] Human immortalized keratinocytes (HaCaT cells) with good growth status were collected and cell suspension was prepared with DMEM complete culture medium. The cell density of the suspension was adjusted to 1.3×10 5 100 μg / mL, 2 mL of cell suspension was added to each well of a 6-well cell culture plate. A blank control group (DMEM high-glucose culture medium), a negative control group (UVB+DMEM high-glucose culture medium), and a sample group (UVB+DMEM high-glucose culture medium containing the composition of Examples 4 to 8 and Comparative Examples 14 to 18) were set up in the experiment, and 3 parallels were set up in each group. The inoculated 6-well cell culture plate was placed in a cell culture incubator (5% CO 2 , 37°C) for 24 h. When the cell fusion rate reached 40-60%, the culture medium was discarded and PBS buffer was added. Except for the blank control group, each group was given 43 mJ / cm 2 The cells were irradiated with a dose of UVB. After the irradiation, the PBS buffer was discarded, new DMEM high-glucose culture medium was added to the blank control group and the negative control group, and the other groups were added with DMEM high-glucose culture medium containing the compositions of Examples 4 to 8 and Comparative Examples 14 to 18, respectively. After culturing in a cell culture incubator for 24 hours, the cell culture medium was aspirated into a 1.5 mL EP tube, centrifuged at 12000 r / min for 10 minutes, the supernatant was taken, and the secretion of TNF-α was determined according to the instructions of the ELISA kit.

[0155] The test concentrations of the compositions of Examples 4 to 8 and Comparative Examples 14 to 18 are shown in Table 1, and the solvent is DMEM high-glucose culture medium.

[0156] TNF-α is in the upstream initiation stage of the inflammatory cascade and is known as an inflammatory sentinel. It is an endogenous pyrogen that can cause skin redness and fever. The test results are shown in Table 10 and Figure 3As shown, after UVB stimulation, the secretion of TNF-α in the negative control group was significantly increased compared with the blank control group (P<0.0001), proving that the light damage model was successfully modeled. After UVB stimulation, compared with the negative control group, after adding the compositions of Examples 4 to 8 and Comparative Examples 14 to 18 to act on damaged cells, the secretion of TNF-α was significantly reduced (P<0.01), wherein the inhibition rates of the compositions of Examples 4 to 8 on the secretion of TNF-α were 84.36%, 88.75%, 72.68%, 76.60%, and 83.84%, respectively, and the inhibition rates of the compositions of Comparative Examples 14 to 18 on the secretion of TNF-α were 53.27%, 10.99%, 70.96%, 70.89%, and 60.44%, respectively. The results of Comparative Examples 14 and 15 show that the use of the skin external prescription extract or glycerol glucoside alone has a certain anti-inflammatory effect, but compared with the results of Examples 4 to 8, it can be seen that the anti-inflammatory effect is significantly improved when the two are used in combination, indicating that the composition of the skin external prescription extract and glycerol glucoside can significantly reduce UVB-induced skin inflammatory response by inhibiting the secretion of TNF-α, play a role in soothing skin inflammation and improving skin photodamage, and can synergistically enhance the effect. Comparative Examples 16 and 17 can be compared with the results of Examples 4 to 8. It can be seen that after one of the skin external prescription extract and glycerol glucoside exceeds a certain concentration range, the increase in content does not improve the inhibitory effect of the composition on TNF-α. At the same time, compared with the results of Example 4, it can be seen that the skin external prescription extract and glycerol glucoside used in the embodiment of the present invention are used in combination. The effect is better.

[0157] Table 10. Effects of the compositions of Examples 4 to 8 and Comparative Examples 14 to 18 on TNF-α secretion in HaCaT cells

[0158] Group Secretion volume (pg / mL) SD value Inhibition rate / % P-value Blank control 424.38 14.07 / / Negative control 903.97 18.22 / <0.0001 Example 4 141.38 12.24 84.36 <0.0001 Example 5 101.68 3.64 88.75 <0.0001 Example 6 246.93 16.43 72.68 <0.0001 Example 7 211.50 16.57 76.60 <0.0001 Example 8 146.07 12.46 83.84 <0.0001 Comparative Example 14 422.43 13.59 53.27 <0.0001 Comparative Example 15 804.59 11.27 10.99 0.0013 Comparative Example 16 262.53 15.45 70.96 <0.0001 Comparative Example 17 263.12 10.15 70.89 <0.0001 Comparative Example 18 357.65 11.23 60.44 <0.0001

[0159] (3) Effects of the compositions of Examples 4 to 8 and Comparative Examples 14 to 18 on the β-endorphin content of HaCaT cells

[0160] Human immortalized keratinocytes (HaCaT cells) with good growth status were collected and cell suspension was prepared with DMEM complete culture medium. The cell density of the suspension was adjusted to 3×10 5 1 mL of cell suspension was added to a 12-well cell culture plate and placed in an incubator (5% CO 2 , 37°C) for 24h. The experiment set up a blank control group (DMEM high-glucose culture medium) and a sample group (DMEM high-glucose culture medium containing the composition of Examples 4 to 8 and Comparative Examples 14 to 18), with 3 parallels in each group. The inoculated 12-well cell culture plate was placed in a cell culture incubator (5% CO 2, 37°C) for 24 h. When the cell fusion rate reached 40-60%, the culture medium was discarded, new DMEM high-glucose culture medium was added to the blank control group, and DMEM high-glucose culture medium containing the compositions of Examples 4 to 8 and Comparative Examples 14 to 18 was added to the sample groups respectively. After culturing in a cell culture incubator for 24 h, the cells were collected, broken by repeated freezing and thawing, and centrifuged at 1500g for 10 min. The supernatant was taken to detect the β-endorphin content.

[0161] The test concentrations of the compositions of Examples 4 to 8 and Comparative Examples 14 to 18 are shown in Table 1, and the solvent is DMEM high-glucose culture medium.

[0162] β-endorphin is one of the important "happy molecules" in the skin. It has local analgesic, immune regulation, repair, anti-inflammatory and soothing effects. It is one of the important targets for solving endogenous skin problems. The test results are shown in Table 11 and Figure 4 As shown, compared with the blank control group, after adding the compositions of Examples 4 to 8 and Comparative Examples 14 to 18 to the cells, except for Comparative Example 14, the β-endorphin contents of the other groups were significantly increased (P<0.01), among which, the increase rates of the compositions of Examples 4 to 8 on the β-endorphin content were 66.51%, 54.58%, 46.43%, 58.98%, and 64.99%, respectively, and the increase rates of the compositions of Comparative Examples 14 to 18 on the β-endorphin content were 0.3%, 18.87%, 45.76%, 44.36%, and 24.10%, respectively. The results of Comparative Example 14 show that the use of the skin external prescription extract alone has no significant effect on the increase of β-endorphin content; the results of Comparative Example 15 show that the use of glycerol glucoside alone has a certain effect on increasing the β-endorphin content, but compared with the results of Examples 4 to 8, it can be seen that the effect of increasing the β-endorphin content when the two are used in combination is better, indicating that the composition of the skin external prescription extract and glycerol glucoside can respond to endogenous skin problems by increasing the β-endorphin content, play a role in improving the skin, and can synergize. Comparative Examples 16 and 17 can be compared with the results of Examples 4 to 8. It can be seen that after one of the skin external prescription extract and glycerol glucoside exceeds a certain concentration range, the increase in content does not increase the effect of the composition on increasing the β-endorphin content. At the same time, compared with the results of Example 4, it can be seen that the skin external prescription extract and glycerol glucoside used in the embodiment of the present invention are used in combination. The effect is better.

[0163] Table 11. Effects of the compositions of Examples 4 to 8 and Comparative Examples 14 to 18 on the β-endorphin content of HaCaT cells

[0164]

[0165]

[0166] (4) Human efficacy testing

[0167] ① Selection and requirements of volunteers: 30 outdoor workers (18 women and 12 men) were selected, with facial skin redness and damaged barrier, and were required to go to bed after 3 am 3 days before the test. All subjects had no history of skin or systemic diseases, no abnormalities in the test area, and did not apply any drugs or cosmetics unrelated to the experiment during the test.

[0168] ②Test environment: The test site is kept at a constant temperature and humidity, with an ambient temperature of 20℃ to 22℃ and a relative humidity of 40% to 60%. The subject should keep the body in a stable state before the test. After washing the subject's face with clean water at about 35℃, sit quietly in the test environment for 30 minutes before starting the test.

[0169] ③ Sample use method: The test samples are the product of Example 9 and the product of Comparative Example 19 (placebo). The matrix of Comparative Example 19 is the same as that of Example 9, except that Comparative Example 19 does not contain the composition consisting of the extract of the skin external prescription and glyceryl glucoside. For self-half face control, use twice a day, once in the morning and evening after cleansing, about 1g of sample each time, for 28 consecutive days.

[0170] ④Test items:

[0171] a. Experimental method: half of the face was used as a control, and the products of Example 9 and Comparative Example 19 were randomly distributed. The transepidermal water loss TEWL, epidermal water content, and facial red area of ​​the subjects' skin after continuous use of the products of Example 9 or Comparative Example 19 on the 0th day and the 28th day were measured using a skin water loss tester (Tewameter, TM300, Courage and Khazaka, Germany), an epidermal water content tester (Corneometer, CM825, Courage and Khazaka, Germany), and a facial imaging system VISIA-CR (Canfield Imaging Systems, Fairfield, NY, USA). The facial red area was analyzed for a* value using Image Pro Plus image analysis software.

[0172] b. Experimental results: The test results are shown in Table 12. After the subjects used the test samples for 28 days, the transepidermal water loss TEWL of the product group of Example 9 was significantly reduced by 14.40%, the epidermal water content was significantly increased by 23.80%, and the skin redness a* value was significantly reduced by 12.22%, while the improvement of the product group of Comparative Example 19 was not obvious. This shows that the product containing the composition composed of the extract of the skin external prescription and glycerol glucoside can improve the skin redness and dryness caused by endogenous and exogenous factors, enhance the skin barrier ability, and thus improve the skin condition.

[0173] Table 12. Skin physiological parameter test results before and after using the samples

[0174]

[0175]

[0176] Note: Compared with comparative example 19, P < 0.05 is considered to be significantly different.

[0177] The above results show that the skin external prescription extract prepared by the present invention can effectively resist oxidative free radicals, reduce skin inflammatory reactions, and promote the expression of barrier-related proteins. The efficacy and stability of the skin external prescription extract obtained by process optimization have been significantly improved, which is more conducive to its application. In addition, the composition composed of the skin external prescription extract and glycerol glucoside has a synergistic effect in reducing skin inflammatory reactions and promoting the expression of barrier-related proteins and β-endorphin, thereby simultaneously coping with the effects of endogenous and exogenous factors on the skin and improving the skin condition.

Claims

1. A method for preparing an extract for external use on skin, characterized in that: The steps include: S1. The medicinal materials of the external skin prescription are crushed separately, passed through a 10-50 mesh sieve, and the sieve portion is taken. The medicinal materials are mixed in a certain proportion and then mixed with an extraction solvent in a certain material-liquid ratio, and extracted by slightly boiling reflux to obtain a crude extract; S2. The crude extract obtained in step S1 is filtered through a filter cloth to remove the drug residue, brought to room temperature, and filtered through a filter plate. After the filtrate is sterilized, it is allowed to stand at room temperature or low temperature for 24 to 48 hours to obtain a secondary filtrate; S3. The secondary filtrate obtained in step S2 is filtered through a filter plate again, a preservative and a stabilizer are added, and the mixture is stirred at 45°C to 55°C until it is completely dissolved, thereby obtaining an extract for external use on the skin.

2. The preparation method according to claim 1, characterized in that The medicinal materials of the skin external application prescription in step S1 include hibiscus leaves, rhubarb, zedoaria leaves, phellodendron, coptis chinensis, scutellaria baicalensis, and borneol, wherein the mass ratio of hibiscus leaves, rhubarb, zedoaria leaves, phellodendron, coptis chinensis, scutellaria baicalensis, and borneol when mixed is 80:80:1:100:80:80:

2.

3. The preparation method according to claim 1, characterized in that: Meet one or more of the following conditions: i. Pass through a 10-mesh sieve in step S1; ii. The extraction solvent in step S1 is 30% to 35% 1,3-butanediol aqueous solution; more preferably 30% 1,3-butanediol aqueous solution, both are mass percentages; iii. The material-liquid ratio in step S1 is 1:(28-32); more preferably 1:30; iv. The temperature of the slightly boiling hot reflux extraction in step S1 is 90 to 100 ° C, and the time is 2 to 4 hours; more preferably, the slightly boiling hot reflux extraction is 100 ° C for 3.5 hours; v. The filter cloth in step S2 is a double-layer filter cloth of 200 to 400 mesh; more preferably a double-layer filter cloth of 300 mesh; vi. The filter plate in steps S2 and S3 is a 0.22 μm or 0.45 μm filter plate; vii. The sterilization in step S2 is performed at 121°C for 20 min; viii. In step S2, stand at room temperature for 36 hours; ix. The low temperature in step S2 is 2 to 6°C; x. The preservative in step S3 is a combination of one or more of 1,2-hexanediol, p-hydroxyacetophenone, and 1,2-pentanediol; further preferably, the preservative is a combination of 1,2-hexanediol, p-hydroxyacetophenone, and 1,2-pentanediol; further preferably, in the extract of the external skin prescription, the final concentration of p-hydroxyacetophenone is 0.3-0.6wt%, the final concentration of 1,2-hexanediol is 0.5-2wt%, and the final concentration of 1,2-pentanediol is 0.5-2wt%; xi. The stabilizer in step S3 is polysorbate 20; further preferably, in the extract of the external skin preparation, the final concentration of polysorbate 20 is 1 to 5 wt%.

4. An extract for external use on skin prepared according to the preparation method of claim 1.

5. A composition for improving skin condition, characterized in that: The invention comprises the extract of the skin external preparation according to claim 4 and glyceryl glucoside.

6. The composition according to claim 5, characterized in that In the system containing the composition, the final concentration of the extract of the skin external prescription is 0.5-6.0 wt %, and the final concentration of the glycerol glucoside is 0.1-2.0 wt %.

7. The composition according to claim 5, characterized in that In the system containing the composition, the final concentration of the extract of the skin external prescription is 1.0-4.0 wt %, and the final concentration of the glycerol glucoside is 1.0-2.0 wt %.

8. Use of the composition according to claim 5 in preparing cosmetics or skin care products.

9. The use according to claim 8, characterized in that The cosmetics or skin care products are in the form of liquid, gel, ointment, cream, lotion, facial mask or freeze-dried powder.

10. A cosmetic or skin care product containing the composition according to claim 5.

Citation Information

Patent Citations

  • Traditional Chinese medicine composition for treating periappendiceal abscess

    CN104971128A

  • Traditional Chinese medicine paste with effects of resisting erysipelas, and subduing swelling and treating mumps

    CN106038780A

  • Traditional Chinese medicine composition for treating skin sores, furuncles, carbuncles, abscess and swelling and pain

    CN111265583A

  • Traditional Chinese medicine plaster for treating mastitis as well as preparation method and application of traditional Chinese medicine plaster

    CN118512516A

  • Acne treating medicine

    CN1634392A